Physician profile
Charles Williams
NPI 1407374002
$4,082.77
in general payments reported to CMS, 2019-2025
25 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $302 · 2022: $442 · 2023: $978 · 2024: $1,272 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,328 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,327.86 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,239.92 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $413.64 | 2022-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $345.22 | 2022-2025 | Wainua, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $273.50 | 2022-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $220.11 | 2024-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.38 | 2022-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $197.22 | 2022-2024 | |
| Altathera Pharmaceuticals LLC | $175.28 | 2023 | Sotalol Hydrochloride |
| Actelion Pharmaceuticals US, INC. | $150.65 | 2023-2024 | Opsumit, Uptravi |
| Amgen INC. | $149.10 | 2023-2024 | Repatha |
| Philips North America LLC | $125.22 | 2022-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided, Extended Holter |
| Medtronic, INC. | $124.15 | 2021-2023 | Cobalt Dr Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.70 | 2024-2025 | Lifevest |
| Pfizer INC. | $69.28 | 2021-2024 | |
| Vivaquant INC, Dba Rhythm Express | $55.96 | 2025 | Rhythm Express |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $51.69 | 2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $37.84 | 2023-2024 | Livalo |
| Lexicon Pharmaceuticals, INC. | $35.17 | 2023-2024 | |
| Bridgebio Pharma, INC. | $23.56 | 2025 | Attruby |
| Cvrx, INC. | $23.22 | 2021 | |
| Impulse Dynamics (USA) INC. | $20.68 | 2022 | |
| Amarin Pharma, INC. | $18.56 | 2023 | |
| Lilly USA, LLC | $16.45 | 2025 | Zepbound |
| Inogen, INC. | $16.39 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Esperion Therapeutics, INC. | $14.88 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.